Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.46 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.46 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.46 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15530847 | 0.84 | NAMPT (0.53) | NAMPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL15530718 | 0.83 | MAPK1 (0.61) | NAMPTPDE4BAPP | |
| SCHEMBL15531384 | 0.81 | NAMPT (0.51) | NAMPTPDE4B | |
| SCHEMBL15530700 | 0.81 | NAMPT (0.54) | NAMPTPDE4BMTNR1BABCC9ABCC8 | |
| SCHEMBL16820411 | 0.80 | HTR2A (0.55) | NAMPTABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL15231829 | 0.79 | HTR6 (0.47) | NAMPTPDE4BABCC9ABCC8KCNJ11 | |
| SCHEMBL6110277 | 0.79 | NFE2L2 (0.50) | NAMPTPDE4BMTNR1BABCC9ABCC8 | |
| SCHEMBL6110207 | 0.79 | NFE2L2 (0.53) | NAMPTMTNR1BNFE2L2 | |
| SCHEMBL15530395 | 0.77 | KMT2A (0.55) | NAMPT | |
| SCHEMBL31352975 | 0.77 | MTNR1B (0.56) | MTNR1BABCC9ABCC8KCNJ11KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | claimed |
| EP-2820017-B1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | GENENTECH INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355514-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | VALO EARLY DISCOVERY, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9458172-B2 | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives | VALO HEALTH, INC. | 2016-10-04 | — | — | US | disclosed |
| US-20150175621-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | Valo Health, LLC | 2015-06-25 | — | — | US | disclosed |
| WO-2013170191-A1 | METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE | GENENTECH, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355514-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | TPMT, TYMS, TYMP | NAMPT 82/4885PDE4B 1809/4885MTNR1B 1098/4885 |
| US-20150175621-A1 | PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES | TPMT, TYMS, TYMP | NAMPT 82/4885PDE4B 1809/4885MTNR1B 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.